Abstract: Disclosed are an interactive information processing method, an electronic device and a storage medium. The method includes establishing a correspondence between a multimedia data stream and a display text generated based on the multimedia data stream; presenting the multimedia data stream and the display text based on the correspondence; and in response to detecting a triggering operation triggering a display content in the display text, adjusting, based on a timestamp corresponding to the display content and the correspondence, the multimedia data stream to navigate to a playback position corresponding to the display content; the display content comprises a text corresponding to speech in the multimedia data stream; and the display text and the multimedia data stream are displayed on different display areas of a page respectively, and a display area occupied by the display text is not superimposed on a display area occupied by the multimedia data stream.

Abstract: The embodiment of the present disclosure relates to a minutes processing method and apparatus, a device, and a storage medium, and the method includes: obtaining a to-be-processed text; performing minutes extraction on the to-be-processed text based on a predetermined minutes categories, and determining a minutes sentence belonging to each predetermined minutes categories; determining another sentence associated with the minutes sentence from the to-be-processed text, and storing an association relationship between each minutes sentence and the corresponding another sentence. Through the technical aspect, it is achieved that the minutes of the to-be-processed text is extracted from multiple dimensions, and compatibility of the minutes to various text forms, minutes information content and query efficiency of the to-be-processed text are improved.

Abstract: Disclosed are an interactive information processing method, an electronic device and a storage medium. The method includes establishing a position correspondence between a display text generated based on a multimedia data stream and the multimedia data stream; and presenting the display text and the multimedia data stream corresponding to the display text based on the position correspondence.

Abstract: A slider comprises an air bearing surface having a leading edge at a first end of the air bearing surface; a trailing edge at a second end of the air bearing surface, wherein the first end is opposite to the second end; a first region adjacent to the trailing edge, wherein the first region comprises one or more transducer elements; and a second region adjacent to the first region and the leading edge. The air bearing surface has a protective overcoat layer as an outermost layer, wherein the protective overcoat layer extends across the entire air bearing surface. The air bearing surface comprises a lapped surface and a plurality of milled surfaces, wherein a surface potential difference between the lapped surface and a milled surface is 0+/?50 milliVolts or less as measured according to Kelvin Probe Force Microscopy (KPFM).

Abstract: The present disclosure relates to kiss lapping sliders after patterning an air bearing surface pattern, followed by applying a protective overcoat to the air bearing surface. The present disclosure also involves related sliders.

Abstract: The present disclosure relates to kiss lapping sliders after patterning an air bearing surface pattern, followed by applying a protective overcoat to the air bearing surface. The present disclosure also involves related sliders.

Abstract: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.

Abstract: A porous chiral material of formula [M(L)1.5(A)]+X? wherein M is a metal ion; L is a nitrogen-containing bidentate ligand; A is the anion of mandelic acid or a related acid; and X? is an anion.

Abstract: A porous chiral material of formula [M(L)1.

Abstract: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.

Abstract: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.

Abstract: Compositions that inhibit or block the interaction between Erbin and ErbB2 and methods of their use are provided. Preferred compositions include peptides that inhibit or block Erbin and ErbB2 interaction under physiologic conditions in a subject. One embodiment provides an isolated peptide fragment of ErbB2 including the C-terminal 15 amino acids of ErbB2. The peptide fragment can be about 15 to 27 amino acids in length.

Abstract: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.

Abstract: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.

Abstract: An apparatus comprising a codec configured to predict an intra mode for a considered block based on a plurality of group numbers and a plurality of corresponding group indices for a plurality used modes of a plurality of adjacent blocks to the considered block, wherein a group number corresponding to an actual intra mode for the considered block is coded and sent if the predicted intra mode does not match the actual intra mode. Also disclosed is a network component comprising a processor configured to predict an intra mode for a considered block based on a minimum group number and a minimum group index of two used modes for two adjacent blocks of the considered block, and a transmitter configured to send coded bits of a group number for an actual intra mode for the considered block if the actual intra mode does not match the predicted intra mode.

Abstract: Compositions that inhibit or block the interaction between Erbin and ErbB2 and methods of their use are provided. Preferred compositions include peptides that inhibit or block Erbin and ErbB2 interaction under physiologic conditions in a subject. One embodiment provides an isolated peptide fragment of ErbB2 including the C-terminal 15 amino acids of ErbB2. The peptide fragment can be about 15 to 27 amino acids in length.

Abstract: Methods and compositions for male or female contraception are provided. The compositions include an effective amount of netrin-1 to reduce or inhibit sperm concentration in semen of males or to inhibit or reduce fusion of male gametes with female gametes in a female subject Still another embodiment provides a method for diagnosing male infertility by determining the amount of netrin-1 in a sample of epididymal fluid or semen from a male subject, comparing the amount of netting-1 in the sample to levels of netrin-1 in samples of epididymal fluid or semen from fertile males, wherein levels of netrin-1 in the sample from the male subject that are higher or lower than levels of netrin-1 in samples from fertile males are indicative of male infertility in the male subject.

Abstract: An apparatus comprising an inter-prediction motion compensation unit, a transform unit coupled to the inter-prediction motion compensation unit, a quantization unit coupled to the transform unit such that the transform unit is positioned between the inter-prediction motion compensation unit and the quantization unit, a scanning unit coupled to the quantization unit such that the quantization unit is positioned between the transform unit and the scanning unit, and an adaptive scan order predictor unit coupled to the inter-prediction motion compensation unit, the quantization unit, and the scanning unit. An apparatus comprising an entropy decoding unit, an inverse scanning unit coupled to the entropy decoding unit, an inverse quantization unit coupled to the inverse scanning unit such that the inverse scanning unit is positioned between the entropy coding unit and the inverse quantization unit, and an adaptive scan order predictor unit coupled to the entropy decoding unit and the inverse scanning unit.

Abstract: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.

Abstract: An apparatus comprising a codec configured to predict an intra mode for a considered block based on a plurality of group numbers and a plurality of corresponding group indices for a plurality used modes of a plurality of adjacent blocks to the considered block, wherein a group number corresponding to an actual intra mode for the considered block is coded and sent if the predicted intra mode does not match the actual intra mode. Also disclosed is a network component comprising a processor configured to predict an intra mode for a considered block based on a minimum group number and a minimum group index of two used modes for two adjacent blocks of the considered block, and a transmitter configured to send coded bits of a group number for an actual intra mode for the considered block if the actual intra mode does not match the predicted intra mode.